MRNA
Moderna, Inc.
Next earnings Jul 30, 2026 (before open) · consensus $-2.12 EPS, $104M rev
Last earnings -1.2% on 2026-05-01
$79.76
▲ +14.43%$79.76▲ +193.67%
over 1Y
L $22.36H $79.76
Earnings Dividend Split Congress buy Congress sellGrouped by date · hover a pin to expand
Today+14.4%
1W+33.5%
1M+74.8%
3M+62.1%
YTD+158.5%
1Y+193.7%
Avoid
Conviction
Horizon
Medium (3–12mo)
Street · 30 analysts
Hold
Revenue in freefall and deep losses, yet priced at 13x sales on a pipeline bet — not investable now.
Revenue $1.94B · FY2025
Moderna's commercial business is collapsing. Revenue fell to $1.94B in FY2025, down 39.9% YoY and a fraction of the $19.3B peak in FY2022, as the COVID franchise (Spikevax, mNEXSPIKE) normalizes. The company remains deeply unprofitable: net income was -$2.82B, operating income -$3.07B, with an operating margin of -158.1%, net margin of -145.2%, and ROE of -32.6%. Operating cash flow was -$1.87B, so the business is still burning cash even after cutting R&D 31.1% to $3.13B and slashing capex 81.7% to $192M.
The one genuine bright spot is the balance sheet, which keeps this from being a near-term solvency story: $2.60B cash (up 34.7%), $8.65B equity, only $590M long-term debt, and a low liabilities/equity ratio of 0.43x. Management further shored up liquidity with a $1.5B five-year term loan facility entered in November 2025 ($600M funded at closing). That runway buys time, but cash and equity are both shrinking and a $1.9B-revenue, multi-billion-loss enterprise will continue to consume that cushion.
AI-generated analysis, produced by our proprietary engine from SEC filing data.
Investment recommendation produced by TENK/calls (tenkcalls.com), Luxembourg. Completed Jun 21, 2026, 3:07 PM ET. Ratings & methodology: definitions · All recommendations to date: track record · Conflicts: disclosures. Not investment advice.
Financials · annual, by fiscal year
| Line item | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|
| Revenue | $18.5B | $19.3B | $6.85B | $3.24B | $1.94B |
| Gross profit | — | — | — | — | — |
| Operating income | $13.3B | $9.42B | -$4.24B | -$3.94B | -$3.07B |
| Net income | $12.2B | $8.36B | -$4.71B | -$3.56B | -$2.82B |
| Diluted EPS | $28.29 | $20.12 | -$12.33 | -$9.28 | -$7.26 |
| Net margin | 66.1% | 43.4% | -68.8% | -110.0% | -145.2% |
Annual figures from SEC 10-K XBRL filings. Open the filing links below for full statement detail.
Key statistics
Valuation
Enterprise value$29.6B
EV / EBITDA—
EV / Sales15.2
EV / FCF—
P / FCF—
PEG (trailing)—
Earnings yield-8.9%
FCF yield-6.5%
Quality & risk
ROIC (est.)-26.3%
Free cash flow-$2.06B
Total debt$590M
Net cash$2.00B
Altman Z-Score5.75 safe
Piotroski F-Score2/8
Capital returns
Buyback yield0.0%
Dividend yield (est.)—
Shareholder yield0.0%
Shares Δ YoY+2.4%
Computed from SEC XBRL annual figures + the current quote. EV and ROIC use long-term + current debt where filed; estimates, not investment advice.
Disclosure timeline
SEC · 8-Ks + reportsRoutine disclosure cadence — no material red flags in recent filings.
Recent filings
all on EDGAR ↗3Period ending 2026-06-152026-06-30open ↗144Filing2026-06-18open ↗4Period ending 2026-06-152026-06-17open ↗144Filing2026-06-15open ↗4Period ending 2026-06-042026-06-08open ↗4Period ending 2026-06-052026-06-08open ↗144Filing2026-06-04open ↗4Period ending 2026-06-012026-06-03open ↗4Period ending 2026-06-012026-06-03open ↗4Period ending 2026-06-012026-06-03open ↗4Period ending 2026-05-272026-05-29open ↗4Period ending 2026-05-272026-05-29open ↗
Frequently asked
- Is Moderna, Inc. (MRNA) a buy?
- MRNA currently carries a Avoid rating with 4/5 conviction, derived from its latest SEC filings. Revenue in freefall and deep losses, yet priced at 13x sales on a pipeline bet — not investable now.
- What is Moderna, Inc.'s quality score?
- MRNA scores 47.88333333333333/100 (grade D) on a SEC-grounded quality model spanning value, growth, profitability, financial health and momentum.
Sources: SEC EDGAR (CIK 0001682852, latest 10-Q filed 2026-05-01) · EODHD · Proprietary analysis · as of 6/21/2026, 7:07:02 PM.
Research and education only — not financial advice. TENKis not a registered investment adviser or broker-dealer and gives no personalized advice. Every call is impersonal — identical for all users, generated on a schedule from SEC filings plus a delayed/third-party price feed — may be wrong or out of date, and is not a recommendation to buy or sell any security. The operator and an affiliated trading operation may hold or trade the securities TENK rates; see Disclosures. Past performance does not guarantee future results. Do your own research.